When does Telix (TLX.AX) report earnings?

Telix (TLX.AX) has an earnings announcement scheduled for 20 Jan 2026. Investors should watch revenue guidance, EPS commentary, and clinical readouts discussed on the call.

What is the current price and valuation for TLX.AX stock?

As of 19 Jan 2026 TLX.AX is **A$11.32** with a market cap near **A$3.89 billion**, price-to-sales **3.28**, and price-to-book **9.17**. Valuation reflects growth expectations.

How does Meyka AI view TLX.AX stock?

Meyka AI rates TLX.AX **68.47 out of 100 (Grade B, HOLD)**. The grade balances clinical opportunity, sector performance, financial growth, and analyst sentiment. This is informational only.

What are the main catalysts that could move TLX.AX stock?

Key catalysts are the BiPASS Phase 3 results, regulatory approvals, reimbursement decisions, and commercial adoption of Illuccix and Gozellix. Positive trial news could substantially re-rate the stock.

AU Stocks

TLX.AX Telix (ASX) A$11.32 19 Jan 2026 ahead of earnings: trial readouts

ByHuzaifa Zahoor January 19, 2026January 19, 2026

TLX.AX stock traded at A$11.32 on 19 Jan 2026, with the company set to report earnings on 20 Jan 2026. Investors are focused on clinical trial updates and how near-term commercial adoption of Illuccix and Gozellix will affect revenue and margins. Telix Pharmaceuticals Limited (TLX.AX) carries high volatility and biotech-specific binary risk tied to study readouts and regulatory pathways. We examine financial ratios, recent catalysts, and the Meyka AI forecast to show what could move the share price at market open tomorrow.